MA31798B1 - Composés organiques - Google Patents

Composés organiques

Info

Publication number
MA31798B1
MA31798B1 MA32804A MA32804A MA31798B1 MA 31798 B1 MA31798 B1 MA 31798B1 MA 32804 A MA32804 A MA 32804A MA 32804 A MA32804 A MA 32804A MA 31798 B1 MA31798 B1 MA 31798B1
Authority
MA
Morocco
Prior art keywords
organic compounds
modulator
parkinson
progression
disease
Prior art date
Application number
MA32804A
Other languages
Arabic (ar)
English (en)
Inventor
Daniel Umbricht
Baltazar Gomez-Mancilla
Fabrizio Gasparini
Paolo Thérése Di
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31798B1 publication Critical patent/MA31798B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

L'INVENTION PORTE SUR L'UTILISATION D'UN MODULATEUR DE MGLUR, PAR EXEMPLE UN MODULATEUR DE MGLUR5, POUR LE TRAITEMENT, LA PRÉVENTION OU RETARDER LA PROGRESSION DE LA MALADIE DE PARKINSON ET DE TROUBLES ASSOCIÉS.
MA32804A 2007-10-12 2010-04-30 Composés organiques MA31798B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97948607P 2007-10-12 2007-10-12
US5033308P 2008-05-05 2008-05-05
PCT/EP2008/063544 WO2009047296A2 (fr) 2007-10-12 2008-10-09 Composés organiques

Publications (1)

Publication Number Publication Date
MA31798B1 true MA31798B1 (fr) 2010-10-01

Family

ID=40348021

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32804A MA31798B1 (fr) 2007-10-12 2010-04-30 Composés organiques

Country Status (19)

Country Link
US (2) US20100249136A1 (fr)
EP (1) EP2211859B1 (fr)
JP (2) JP5743545B2 (fr)
KR (1) KR101572280B1 (fr)
CN (1) CN101854935A (fr)
AU (1) AU2008309621A1 (fr)
BR (1) BRPI0818560A2 (fr)
CA (1) CA2701853A1 (fr)
CL (1) CL2008003006A1 (fr)
IL (1) IL204954A0 (fr)
MA (1) MA31798B1 (fr)
MX (1) MX2010003913A (fr)
NZ (1) NZ584856A (fr)
RU (1) RU2508107C2 (fr)
SG (1) SG185293A1 (fr)
TN (1) TN2010000155A1 (fr)
TW (1) TW200924745A (fr)
WO (1) WO2009047296A2 (fr)
ZA (1) ZA201002423B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009265760B2 (en) 2008-06-30 2013-07-18 Novartis Ag Combinations comprising mGluR modulators for the treatment of parkinson's disease
US8084487B2 (en) * 2008-08-12 2011-12-27 Novartis Ag Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof
WO2011035209A1 (fr) * 2009-09-17 2011-03-24 Vanderbilt Universtiy Analogues de benzamide substitué en tant que modulateurs allostériques négatifs mglur5, et leurs procédés de préparation et d'utilisation
EP2680849A4 (fr) * 2011-03-03 2015-02-18 Univ Vanderbilt Analogues de 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide en tant que modulateurs allostériques négatifs de mglur5 et procédé pour les préparer et les utiliser
BR112013023813A2 (pt) 2011-03-18 2016-12-13 Novartis Ag combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson
GB201204962D0 (en) 2012-03-21 2012-05-02 Addex Pharmaceuticals Sa Pharmaceutical combination products for parkinsons disease
EP3071568A1 (fr) 2013-11-19 2016-09-28 Vanderbilt University Composés imidazopyridine et triazolopyridine substitués utilisés comme modulateurs allostériques négatifs de mglur
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
KR101749675B1 (ko) * 2015-07-20 2017-06-26 동국대학교 산학협력단 멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
CH1196397H1 (de) * 1999-06-02 2007-05-31 Nps Pharma Inc Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems.
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US7105548B2 (en) * 2001-12-18 2006-09-12 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
EP1539749A4 (fr) * 2002-09-13 2007-06-13 Merck & Co Inc Modulateurs du recepteur glutamate metabotropique 5 (mglur5) de phenyle substitues par un fragment heterobicyclo fusionne
EP1596808A4 (fr) * 2003-02-07 2007-04-04 Yissum Res Dev Co Derives d'amide l-dopa et utilisations de ceux-ci
WO2005030128A2 (fr) * 2003-09-23 2005-04-07 Merck & Co., Inc. Modulateurs pyrazole de recepteurs de glutamate metabotropiques
WO2005079802A1 (fr) * 2004-02-12 2005-09-01 Merck & Co., Inc. Amides bipyridyles en tant que modulateurs du récepteur-5 métabotropique du glutamate
BRPI0607583A2 (pt) * 2005-03-04 2009-09-15 Hoffmann La Roche derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
GB0508318D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508319D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
TW200801005A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
CA2627630A1 (fr) * 2005-12-20 2007-06-28 Novartis Ag Derives d'acide nicotinique en tant que modulateurs des recepteurs metabotropiques du glutamate
WO2008031550A2 (fr) * 2006-09-11 2008-03-20 Novartis Ag Nouvelles utilisations de récepteurs de glutamate métabotropiques
AU2009265760B2 (en) * 2008-06-30 2013-07-18 Novartis Ag Combinations comprising mGluR modulators for the treatment of parkinson's disease

Also Published As

Publication number Publication date
WO2009047296A2 (fr) 2009-04-16
EP2211859B1 (fr) 2016-01-06
NZ584856A (en) 2012-12-21
AU2008309621A1 (en) 2009-04-16
US20150272929A1 (en) 2015-10-01
JP2014240425A (ja) 2014-12-25
JP2011500529A (ja) 2011-01-06
JP5743545B2 (ja) 2015-07-01
ZA201002423B (en) 2010-12-29
KR101572280B1 (ko) 2015-11-26
WO2009047296A3 (fr) 2009-08-20
IL204954A0 (en) 2010-11-30
BRPI0818560A2 (pt) 2019-09-24
US20100249136A1 (en) 2010-09-30
MX2010003913A (es) 2010-04-27
CL2008003006A1 (es) 2009-05-08
RU2508107C2 (ru) 2014-02-27
EP2211859A2 (fr) 2010-08-04
CA2701853A1 (fr) 2009-04-16
SG185293A1 (en) 2012-11-29
TW200924745A (en) 2009-06-16
TN2010000155A1 (en) 2011-11-11
CN101854935A (zh) 2010-10-06
RU2010118454A (ru) 2011-11-20
KR20100088136A (ko) 2010-08-06

Similar Documents

Publication Publication Date Title
MA31798B1 (fr) Composés organiques
FR19C1005I2 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
FR2920305B1 (fr) Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
MA31156B1 (fr) Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
FR13C0030I1 (fr) Compositions pour le traitement de troubles gastrointestinaux
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA32904B1 (fr) Composes de purine
MA29316B1 (fr) Derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
MA32506B1 (fr) Nouveaux composes
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
MA32462B1 (fr) Dronedarone dans le traitement prophylactique de la fibrillation auriculaire permanente
FR2891460B1 (fr) Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
FR2921795B1 (fr) Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
FR2919501B1 (fr) Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees
FR2930153B1 (fr) Utilisation d'un extrait de baie, et plus particulierement de wolfberry, pour le traitement de la secheresse des matieres keratiniques
FR2896422B1 (fr) Systeme de drainage pour le traitement de l'hydrocephalie
FR3084255B1 (fr) Souche de streptococcus thermophilus cnrz160 pour le traitement et la prevention de l'inflammation intestinale et des desordres associes, chez un individu
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
WO2007120605A3 (fr) Traitement d'une maladie pulmonaire induite par la nicotine utilisant des agonistes gamma du recepteur active du proliferateur du peroxisome
FR2906468B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
MA32482B1 (fr) Utilisation d'inhibiteurs de hdac pour le traitement de la maladie de hodgkin
FR2902326B1 (fr) Utilisation de la coumarine, de butylated hydroxyanisole et d'ethoxyquine pour le traitement de la canitie